NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

1) I do not think the company charged $200,000 always, but less. Like around $150,000 for a long time. It is also possible that those revenues may have come in through a subsidiary, and be reflected in a less obvious manner. I do not claim to know for sure, but I do think it is possible, especially since the regulator may think any suggestion of wide availability is problematic pre-approval. Thus they may have made a serious effort to ensure such treatments are extremely confidential.

2) I do not think the past time period is only the years you included. In fact I think the years you included there was not a lot of compassionate care until they got Sawston licensed for compassionate care.

3) the disease is fast and not everyone has that kind of money immediately. Further, so in that intervening period, I do not think compassionate care information was widely known. The journal article was not yet published, and if you’re a patient contemplating raising the funds, a) you’d have to wait for certification and you probably wanted to wait for results to be published.

4) with all the licensing and word getting out since late November, some small percentage of patients may likely be able to raise those funds. But if you follow a lot of those patients using go fund me and other tools, their fundraising has not been easy this last year or so. Not rapid, at least.

5) patients had to have had doctors that actually kept the resected tumor in the proper condition and frozen immediately. I would expect that most patients would have had surgery without that being part of the protocol last year, especially if a) they did not have the money; and b) they had never heard of the DCVax-L results prior to publication, or even after.

Their doctors would have had to have told them and I would bet if patients do not look like raising that kind of money is no big deal, doctors may even be hesitant to add to their misery by telling them about this option that looks like it is way out of their financial reach.

Whatever the case, I believe with results out, more doctors will have heard and will be advising patients to freeze their tumors. So now it won’t seem crazy to do that, and to take the precaution and send it to the company with the anticipation that somehow they will make it happen. But they still have to raise the funds. There will no doubt be a lag time. But I think any patient and their family would be hoping for this. On the other hand, Optune costs an arm and a leg more than DCVax, it is immediately available and is not covered by the NHS. It is claimed to deliver similar results and the doctors who make a lot of money on it are very partisan about it. It’s approved and costs $250,000 a year approximately. Because it is approved and not covered, and many doctors are pushing it, I expect that a lot of patients, at least until recently, spent their last dollars on Optune. But that will change. And DCVax-L appears to be way more affordable over the long-run and clearly has great potential, especially with poly iclc and Keytruda of seriously extending those patient’s lives, with far less discomfort, inconvenience and expense.

However, the company here and there has described a large number of patients who have received DCVax-L for various cancers including DCVax-L outside of the trial data.

For instance, here https://nwbio.com/nw-bio-provides-update-about-phase-iii-dcvax-l-trial-for-gbm-and-information-arm-compassionate-use-case-patients/

Though I do believe that was likely provided as a study and probably free. That was 55 compassionate care patients.

I do believe they have had a variety of patients throughout the two trials for DCVax-L and DCVax Direct who may have received compassionate care, over at least a decade. So they would not likely be in the numbers you attempted to use to demonstrate no such patients ever having received compassionate care. But they do exist. Also, some spoke during the ASCO presentation a few years ago, I believe in 2018 or 2019.